Biosynthema Overview

  • Year Founded
  • 2001

Year Founded

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

Biosynthema General Information

Description

Developer of unique pharmaceuticals intended to target cell surface receptors overexpressed in cancer cells. The company develops technology that makes specific tumors highly visible using diagnostic imaging methods, thereby enabling earlier and more accurate diagnosis of cancer and treatment of neuroendocrine tumors.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Corporate Office
  • 4041 Forest Park Avenue
  • Saint Louis, MO 63108
  • United States
+1 (314) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Biosynthema Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Biosynthema‘s full profile, request access.

Request a free trial

Biosynthema Executive Team (1)

Name Title Board Seat Contact Info
Jack Erion Ph.D President and Chief Executive Officer
To view Biosynthema’s complete executive team members history, request access »

Biosynthema FAQs

  • When was Biosynthema founded?

    Biosynthema was founded in 2001.

  • Who is the CEO of Biosynthema?

    Jack Erion Ph.D is the CEO of Biosynthema.

  • Where is Biosynthema headquartered?

    Biosynthema is headquartered in Saint Louis, MO.

  • What industry is Biosynthema in?

    Biosynthema’s primary industry is Biotechnology.

  • Is Biosynthema a private or public company?

    Biosynthema is a Private company.

  • What is Biosynthema’s current revenue?

    The current revenue for Biosynthema is 000000.

  • When was Biosynthema acquired?

    Biosynthema was acquired on 01-May-2010.

  • Who acquired Biosynthema?

    Biosynthema was acquired by Advanced Accelerator Applications.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »